Clinical Trials Logo

Coronavirus Infections clinical trials

View clinical trials related to Coronavirus Infections.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04657406 Available - Covid19 Clinical Trials

Expanded Access to Zofin for Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

NCT ID: NCT04456439 Available - Clinical trials for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

NCT ID: NCT04288713 Available - Coronavirus Clinical Trials

Eculizumab (Soliris) in Covid-19 Infected Patients

SOLID-C19
Start date: n/a
Phase:
Study type: Expanded Access

Covid-19 has spread rapidly throughout the world causing widespread panic, death, and injury. While this virus is the provocateur, it is often the patient's own disproportionate immune response which deals the most devastating (and often fatal) damage. A specific part of the immune system, known as the complement, has been shown to cause such damage in other types of coronaviruses. In the SOLID-C19 study, Soliris (Eculizumab) will be used to modulate the activity of the distal complement preventing the formation of the membrane attack complex. By modulating this portion of the immune response, mortality can be halted while the patient has time to recover from the virus with supportive medical care.